rasagiline has been researched along with Glioblastoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Inaba-Hasegawa, K; Maruyama, W; Naoi, M; Shamoto-Nagai, M | 1 |
| Johnson, C; Johnson, S; Lu, D; Ou, XM; Stockmeier, CA; Tazik, S; Youdim, MB | 1 |
2 other study(ies) available for rasagiline and Glioblastoma
| Article | Year |
|---|---|
Type B and A monoamine oxidase and their inhibitors regulate the gene expression of Bcl-2 and neurotrophic factors in human glioblastoma U118MG cells: different signal pathways for neuroprotection by selegiline and rasagiline.
Topics: Antineoplastic Agents; Apoptosis; Astrocytes; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glioblastoma; Humans; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nerve Growth Factors; Neuroprotection; Neuroprotective Agents; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Selegiline; Signal Transduction | 2017 |
Comparative neuroprotective effects of rasagiline and aminoindan with selegiline on dexamethasone-induced brain cell apoptosis.
Topics: Analysis of Variance; Anti-Inflammatory Agents; Apoptosis; Brain; Cell Line, Tumor; Dexamethasone; Dose-Response Relationship, Drug; Glioblastoma; Humans; In Situ Nick-End Labeling; Indans; Monoamine Oxidase; Neuroblastoma; Neuroprotective Agents; Selegiline; Tetrazolium Salts; Thiazoles | 2009 |